World's First DNA Based COVID-19 Vaccine ZyCoV-D Receives Em
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
World’s first and India’s indigenously developed DNA based ZyCoV-D vaccine developed by Zydus Cadila for COVID-19 to be administered in humans including children and adults 12 years and above, has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI).

Developed in partnership with the Department of Biotechnology (DB), Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 research consortia through National Biopharma Mission for preclinical studies, Phase I and Phase II clinical trials and under the mission COVID Suraksha for phase III clinical trial.

The 3 dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance. The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Interim results from phase-III clinical trials, in over 28,000 volunteers, showed primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19. This vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier. Both the Phase I/II and Phase III clinical trials have been monitored by an independent Data Safety Monitoring Board (DSMB).